Counseling Points Multiple Sclerosis - Spring 2015 - 12

clinical trial programme with a focus on adverse events of interest in RA

43. Edan G, Le Page E. Induction therapy for patients with multiple sclerosis:

patients. Ann Rheum Dis. 2013;72(9):1496-1502.

why? When? How? CNS Drugs. 2013;27(6):403-409.
44. Heesen C, Kleiter I, Nguyen F, et al. Risk perception in natalizumab-

34. Warnke C, Stuve O, Kieseier BC. Teriflunomide for the treatment of mul-

treated multiple sclerosis patients and their neurologists. Mult Scler.

tiple sclerosis. Clin Neurol Neurosurg. 2013;115 Suppl 1:S90-94.

2010;16(12):1507-1512.

35. van Oosten BW, Killestein J, Barkhof F, et al. PML in a patient treated

45. Kaphingst KA, DeJong W. The educational potential of direct-to-con-

with dimethyl fumarate from a compounding pharmacy. N Engl J Med.

sumer prescription drug advertising. Health Aff (Millwood). 2004;23(4):

2013;368(17):1658-1659.

143-150.

36. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N

46. Khanfar N, Loudon D, Sircar-Ramsewak F. FDA direct-to-consumer

Engl J Med. 2013;368(17):1657-1658.

advertising for prescription drugs: what are consumer preferences and

37. Johnson KP. Glatiramer acetate for treatment of relapsing-remitting mul-

response tendencies? Health Mark Q. 2007;24(1-2):77-91.

tiple sclerosis. Expert Rev Neurother. 2012;12(4):371-384.

47. Fox R, Salter A, Alster JM, et al. Risk tolerance in MS patients: Survey

38. Garcia-Montojo M, De Las Heras V, Bartolome M, et al. Interferon

results from the NARCOMS Registry. Neurology. 2011;76(Suppl 4):A478;

beta treatment: bioavailability and antiviral activity in multiple sclerosis

Abstract P06.057.

patients. J Neurovirol. 2007;13(6):504-512.

48. Heesen C, Kopke S, Richter T, et al. Shared decision making and self-

39. Carr DJ, Al-khatib K, James CM, et al. Interferon-beta suppresses herpes

management in multiple sclerosis--a consequence of evidence. J Neurol.

simplex virus type 1 replication in trigeminal ganglion cells through an

2007;254 Suppl 2:II116-121.

RNase L-dependent pathway. J Neuroimmmunol. 2003;141(1-2):40-46.

49. Clanet MC, Wolinsky JS, Ashton RJ, et al. Risk evaluation and monitoring

40. Miller CS, Houff SA, Hopper J, et al. Disease-modifying drugs for multiple

in multiple sclerosis therapeutics. Mult Scler. 2014;20(10):1306-1311.

sclerosis and JC virus expression. J Neurovirol. 2012;18(5):411-415.

50. Bermel RA, Puli SR, Rudick RA, et al. Prediction of longitudinal brain atro-

41. Moore RA, Derry S, McQuay HJ, et al. What do we know about communi-

phy in multiple sclerosis by gray matter magnetic resonance imaging T2

cating risk? A brief review and suggestion for contextualising serious, but

hypointensity. Arch Neurol. 2005;62(9):1371-1376.

rare, risk, and the example of cox-2 selective and non-selective NSAIDs.

51. Cohen JP, Felix AE. Personalized Medicine's Bottleneck: Diagnostic Test

Arthritis Res Ther. 2008;10(1):R20.

Evidence and Reimbursement. J Pers Med. 2014;4(2):163-175.

42. Menon S, Shirani A, Zhao Y, et al. Characterising aggressive multiple scle-

52. CoverMyMeds Prior Authorization Software. Available at: http://www.
covermymeds.com.

rosis. J Neurol Neurosurg Psychiatry. 2013.

www.counselingpoints.com

12



Counseling Points Multiple Sclerosis - Spring 2015

Table of Contents for the Digital Edition of Counseling Points Multiple Sclerosis - Spring 2015

Counseling Points Multiple Sclerosis - Spring 2015 - 1
Counseling Points Multiple Sclerosis - Spring 2015 - 2
Counseling Points Multiple Sclerosis - Spring 2015 - 3
Counseling Points Multiple Sclerosis - Spring 2015 - 4
Counseling Points Multiple Sclerosis - Spring 2015 - 5
Counseling Points Multiple Sclerosis - Spring 2015 - 6
Counseling Points Multiple Sclerosis - Spring 2015 - 7
Counseling Points Multiple Sclerosis - Spring 2015 - 8
Counseling Points Multiple Sclerosis - Spring 2015 - 9
Counseling Points Multiple Sclerosis - Spring 2015 - 10
Counseling Points Multiple Sclerosis - Spring 2015 - 11
Counseling Points Multiple Sclerosis - Spring 2015 - 12
Counseling Points Multiple Sclerosis - Spring 2015 - 13
Counseling Points Multiple Sclerosis - Spring 2015 - 14
Counseling Points Multiple Sclerosis - Spring 2015 - 15
Counseling Points Multiple Sclerosis - Spring 2015 - 16
https://www.nxtbookmedia.com